Searching for new options for treating insomnia: Are melatonin and ramelteon beneficial?

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Insomnia is one of the most common complaints faced in clinical practice. The limited pharmacological options available make the treatment of this complaint a challenge. All of the available benzodiazepines and non-benzodiazepine hypnotics have the potential to induce addiction, cause withdrawal symptoms, or trigger rebound insomnia. Further, the evidence supporting the utility of commonly prescribed options such as antidepressants and antipsychotics is limited. Melatonin is a hormone that has been associated with soporific effects. Based on this premise, a melatonin receptor agonist was created. Ramelteon was approved by the Food and Drug Administration in 2005 and is the only medication indicated for the long-term treatment of insomnia. A critical review with a clinical perspective of randomized, placebo-controlled clinical trials was conducted to determine the efficacy of melatonin and ramelteon for the treatment of insomnia. Based on this review, it appears that more placebo-controlled trials are indicated before valid judgments concerning the efficacy of both melatonin and ramelteon can be made. In the meantime, there is some support for the use of melatonin for the treatment of insomnia, and findings concerning ramelteon also appear promising. Nevertheless, clinicians who prescribe melatonin or ramelteon should be cautious and carefully monitor both potential benefits and adverse effects, since data on melatonin are based on studies with multiple limitations and only three controlled trials have been done with ramelteon.

Original languageEnglish (US)
Pages (from-to)229-243
Number of pages15
JournalJournal of Psychiatric Practice
Volume12
Issue number4
DOIs
StatePublished - Jul 1 2006

Fingerprint

Sleep Initiation and Maintenance Disorders
Melatonin
Placebos
Melatonin Receptors
Substance Withdrawal Syndrome
United States Food and Drug Administration
Therapeutics
Hypnotics and Sedatives
Benzodiazepines
Antidepressive Agents
Antipsychotic Agents
ramelteon
Randomized Controlled Trials
Hormones
Pharmacology

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

@article{b603275acd794f389dcbd2b0346adb31,
title = "Searching for new options for treating insomnia: Are melatonin and ramelteon beneficial?",
abstract = "Insomnia is one of the most common complaints faced in clinical practice. The limited pharmacological options available make the treatment of this complaint a challenge. All of the available benzodiazepines and non-benzodiazepine hypnotics have the potential to induce addiction, cause withdrawal symptoms, or trigger rebound insomnia. Further, the evidence supporting the utility of commonly prescribed options such as antidepressants and antipsychotics is limited. Melatonin is a hormone that has been associated with soporific effects. Based on this premise, a melatonin receptor agonist was created. Ramelteon was approved by the Food and Drug Administration in 2005 and is the only medication indicated for the long-term treatment of insomnia. A critical review with a clinical perspective of randomized, placebo-controlled clinical trials was conducted to determine the efficacy of melatonin and ramelteon for the treatment of insomnia. Based on this review, it appears that more placebo-controlled trials are indicated before valid judgments concerning the efficacy of both melatonin and ramelteon can be made. In the meantime, there is some support for the use of melatonin for the treatment of insomnia, and findings concerning ramelteon also appear promising. Nevertheless, clinicians who prescribe melatonin or ramelteon should be cautious and carefully monitor both potential benefits and adverse effects, since data on melatonin are based on studies with multiple limitations and only three controlled trials have been done with ramelteon.",
author = "Alfredo Bellon",
year = "2006",
month = "7",
day = "1",
doi = "10.1097/00131746-200607000-00005",
language = "English (US)",
volume = "12",
pages = "229--243",
journal = "Journal of Psychiatric Practice",
issn = "1527-4160",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Searching for new options for treating insomnia : Are melatonin and ramelteon beneficial? / Bellon, Alfredo.

In: Journal of Psychiatric Practice, Vol. 12, No. 4, 01.07.2006, p. 229-243.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Searching for new options for treating insomnia

T2 - Are melatonin and ramelteon beneficial?

AU - Bellon, Alfredo

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Insomnia is one of the most common complaints faced in clinical practice. The limited pharmacological options available make the treatment of this complaint a challenge. All of the available benzodiazepines and non-benzodiazepine hypnotics have the potential to induce addiction, cause withdrawal symptoms, or trigger rebound insomnia. Further, the evidence supporting the utility of commonly prescribed options such as antidepressants and antipsychotics is limited. Melatonin is a hormone that has been associated with soporific effects. Based on this premise, a melatonin receptor agonist was created. Ramelteon was approved by the Food and Drug Administration in 2005 and is the only medication indicated for the long-term treatment of insomnia. A critical review with a clinical perspective of randomized, placebo-controlled clinical trials was conducted to determine the efficacy of melatonin and ramelteon for the treatment of insomnia. Based on this review, it appears that more placebo-controlled trials are indicated before valid judgments concerning the efficacy of both melatonin and ramelteon can be made. In the meantime, there is some support for the use of melatonin for the treatment of insomnia, and findings concerning ramelteon also appear promising. Nevertheless, clinicians who prescribe melatonin or ramelteon should be cautious and carefully monitor both potential benefits and adverse effects, since data on melatonin are based on studies with multiple limitations and only three controlled trials have been done with ramelteon.

AB - Insomnia is one of the most common complaints faced in clinical practice. The limited pharmacological options available make the treatment of this complaint a challenge. All of the available benzodiazepines and non-benzodiazepine hypnotics have the potential to induce addiction, cause withdrawal symptoms, or trigger rebound insomnia. Further, the evidence supporting the utility of commonly prescribed options such as antidepressants and antipsychotics is limited. Melatonin is a hormone that has been associated with soporific effects. Based on this premise, a melatonin receptor agonist was created. Ramelteon was approved by the Food and Drug Administration in 2005 and is the only medication indicated for the long-term treatment of insomnia. A critical review with a clinical perspective of randomized, placebo-controlled clinical trials was conducted to determine the efficacy of melatonin and ramelteon for the treatment of insomnia. Based on this review, it appears that more placebo-controlled trials are indicated before valid judgments concerning the efficacy of both melatonin and ramelteon can be made. In the meantime, there is some support for the use of melatonin for the treatment of insomnia, and findings concerning ramelteon also appear promising. Nevertheless, clinicians who prescribe melatonin or ramelteon should be cautious and carefully monitor both potential benefits and adverse effects, since data on melatonin are based on studies with multiple limitations and only three controlled trials have been done with ramelteon.

UR - http://www.scopus.com/inward/record.url?scp=33746858161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746858161&partnerID=8YFLogxK

U2 - 10.1097/00131746-200607000-00005

DO - 10.1097/00131746-200607000-00005

M3 - Review article

C2 - 16883148

AN - SCOPUS:33746858161

VL - 12

SP - 229

EP - 243

JO - Journal of Psychiatric Practice

JF - Journal of Psychiatric Practice

SN - 1527-4160

IS - 4

ER -